Clinical trial Recruiting at 1 site Interventional Ages 50 to 100

Comparing iStent and laser treatment for exfoliation glaucoma during cataract surgery

Official title: A Prospective Randomised Trial Comparing Selective Laser Trabeculoplasty (SLT) and iStent Trabecular Micro-bypass Stent Implantation Combined With Cataract Surgery in Exfoliation Glaucoma

Run by Helsinki University Central Hospital · NCT04635020 · Data updated 2026-11-12

This study is testing whether using the iStent or laser treatment during cataract surgery helps people with exfoliation glaucoma see better compared to just having cataract surgery alone.

Quick facts

Study typeInterventional
Ages50 Years to 100 Years
SexAll
Enrollment285 (estimated)
SponsorHelsinki University Central Hospital
Academic / other
Locations1 site (Helsinki)
StatusRecruiting
StartedOctober 1, 2020
Main results expectedSeptember 2023
Study endsSeptember 2033
Registry record updatedNovember 18, 2020
Trial IDNCT04635020 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients with mild to moderate exfoliation glaucoma and significant cataracts who can attend follow-up visits for 12 months.

Probably not a fit

Patients with advanced glaucoma or those unable to use topical medical therapy may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of the iStent trabecular microbypass stent compared to selective laser trabeculoplasty (SLT) in patients with exfoliation glaucoma undergoing cataract surgery. Patients with stable or unstable glaucoma will be randomized into different treatment groups: one receiving cataract surgery with iStent, another with SLT, and a control group undergoing cataract surgery alone. The study aims to assess the outcomes of these interventions over a 12-month period. All participants will provide informed consent and undergo screening to determine their eligibility based on specific glaucoma criteria.

Why it matters

Potential benefit: If successful, this study could provide a more effective treatment option for patients with exfoliation glaucoma undergoing cataract surgery.

How similar studies have gone: Other studies have shown promising results with similar approaches, but this specific comparison is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Signed consent of information
* Clinical significant cataract
* Able to attend 12 month period
* Mild to moderate exfoliation glaucoma according to European glaucoma society guidelines (EGS)
* Group I stable glaucoma (IOP within individual target IOP), and group II unstable glaucoma (IOP above individual target IOP) with baseline glaucoma medication
* Target IOP ≥16
* Able to understand Finnish, Swedish or English

Exclusion Criteria:

* Clinical set target IOP \< 16 mmHg in advanced glaucoma
* Baseline IOP prior to enrolment ≥30 mmHg, and ≥3 glaucoma medications
* Closed angle
* Congenital angle anomaly
* Clinically significant corneal dystrophy or other hindering corneal condition
* Unable to use topical medical therapy
* Central corneal thickness of less than 480um or more than 620um
* Active uveitis, cystic macular edema (CME), exudative age-related macular degeneration, proliferative diabetic retinopathy or clinical significant macular edema, intraocular neoplasm, intraocular injections, intraocular lens luxation, phacodonesis.
* Previous intraocular surgery, refractive surgery or cycloablation
* Two or more prior SLT or laser trabeculoplasty
* Unable to participate due to another medical disease or condition
* Participating in another clinical trial

Where it's running

  • Helsinki University Hospital
    Helsinki, Finland
    Recruiting

Study contacts

  • Principal investigator: Mika Harju, MD, prof. — Helsinki University Central Hospital
  • Study coordinator: Eeva Ojanen, MD
  • Email: eeva.ojanen@hus.fi
  • Phone: +358503608589

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.